-
Precision BioSciences Reports Clinical Evidence of cccDNA Elimination with Gene Editing Therapy for Chronic Hepatitis B
Aug 06 2026 -
Sarepta Reports Q2 2026 Results as Precision Genetic Medicine Pipeline Advances Toward Key Clinical Readouts
Aug 05 2026 -
Tenaya Reports Clinical Progress for AAV Gene Therapies TN-201 and TN-401 in Inherited Cardiomyopathies
Aug 05 2026 -
Galibra Receives FDA Orphan Drug and Rare Pediatric Disease Designations for AAV Gene Therapy in SSADH Deficiency
Aug 05 2026 -
Kriya Reports Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged Mice
Aug 05 2026 -
Eli Lilly Discontinues AAV-Based GBA1 Gene Therapy Trial in Gaucher Disease Type 1
Aug 05 2026 -
Obsidian Completes Galera Merger and $350M Financing to Advance Engineered TIL Cell Therapies
Aug 03 2026 -
Estrella Activates Third Clinical Site for EB103 T-Cell Therapy Trial
Aug 03 2026 -
Rocket Reports Early Safety Update for AAV9 Gene Therapy RP-A501 in Danon Disease
Aug 03 2026